Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations
Carlos Caulin, … , Guillermina Lozano, Dennis R. Roop
Carlos Caulin, … , Guillermina Lozano, Dennis R. Roop
Published July 2, 2007
Citation Information: J Clin Invest. 2007;117(7):1893-1901. https://doi.org/10.1172/JCI31721.
View: Text | PDF
Research Article

An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations

  • Text
  • PDF
Abstract

Mutations in ras and p53 are the most prevalent mutations found in human nonmelanoma skin cancers. Although some p53 mutations cause a loss of function, most result in expression of altered forms of p53, which may exhibit gain-of-function properties. Therefore, understanding the consequences of acquiring p53 gain-of-function versus loss-of-function mutations is critical for the generation of effective therapies for tumors harboring p53 mutations. Here we describe an inducible mouse model in which skin tumor formation is initiated by activation of an endogenous K-rasG12D allele. Using this model we compared the consequences of activating the p53 gain-of-function mutation p53R172H and of deleting the p53 gene. Activation of the p53R172H allele resulted in increased skin tumor formation, accelerated tumor progression, and induction of metastasis compared with deletion of p53. Consistent with these observations, the p53R172H tumors exhibited aneuploidy associated with centrosome amplification, which may underlie the mechanism by which p53R172H exerts its oncogenic properties. These results clearly demonstrate that p53 gain-of-function mutations confer poorer prognosis than loss of p53 during skin carcinogenesis and have important implications for the future design of therapies for tumors that exhibit p53 gain-of-function mutations.

Authors

Carlos Caulin, Thao Nguyen, Gene A. Lang, Thea M. Goepfert, Bill R. Brinkley, Wei-Wen Cai, Guillermina Lozano, Dennis R. Roop

×

Figure 1

K-ras activation initiates skin tumor formation.

Options: View larger image (or click on image) Download as PowerPoint

K-ras activation initiates skin tumor formation.
(A) Gross appearance o...
(A) Gross appearance of the epidermal papillomas that developed in the skin of RU486-treated K5Cre*-Ras mice 16 weeks after exposure to TPA. (B) Schematic representation of the LSL–K-rasG12D allele. The glycine–to–aspartic acid mutation (asterisk) in codon 12 is located in exon 1 (E1). Primers 1 and 2 (P1 and P2) were used for analysis of excision of the stop cassette. (C) Activation of the K-rasG12D allele in the skin (lanes 1 and 2) and papillomas (lanes 3, 4, and 5) of K5Cre*-Ras mice. Note that the K-rasG12D allele is only activated in RU486-treated skin (lane 2), but not in untreated mice (lane 1). (D) Hematoxylin and eosin staining of papillomas that developed in K5Cre*-Ras mice. (E and F) Keratin staining in papillomas: double immunofluorescence for K14 (red) and K13 (green) (E) and K14 (red) and K6 (green) (F) on frozen sections obtained from papillomas that developed in K5Cre*-Ras mice. Original magnification, ×40 (D), ×100 (E and F).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts